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Abstract: The charge of the Molecular Biology, Genomics, and
Proteomics in Bronchioloalveolar Carcinoma Committee was to
evaluate the molecular biology, genomic changes, and proteomic
findings in patients with bronchioloalveolar carcinoma compared
with other types of lung cancer. The literature was reviewed and
unpublished information was presented by the committee members
at the session. The molecular biology studies have included findings
on epidermal growth factor receptor (EGFR) mutations, p53 muta-
tions, K-ras mutations, and loss of heterozygosity. The genomic
changes have mostly focused on the mRNA expression arrays as
well as protein studies. The current state of knowledge was re-
viewed, the missing information was acknowledged, and proposals
for future research were identified.
KeyWords: Lung neoplasm, Adenocarcinoma, Bronchioloalveolar,
Adenocarcinoma, Carcinoma, Non-small cell lung cancer.
(J Thorac Oncol. 2006;1: S8–S12)
Little information is available about p53 mutations and p53protein overexpression detected by immunohistochemis-
try, microsatellite loss of heterozygosity (LOH), and K-ras
mutations in adenocarcinoma of the bronchioloalveolar sub-
type, according to the last World Health Organization (WHO)
pathological classification proposed in 1999. However, the
frequency of these molecular abnormalities seems to increase
during the multistep process of carcinogenesis of peripheral
adenocarcinoma going from atypical alveolar hyperplasia
adenocarcinoma to bronchioloalveolar carcinoma (BAC) and
to invasive adenocarcinoma.
ATYPICAL ADENOMATOUS HYPERPLASIA
There is an increasing body of evidence to support the
concept of atypical adenomatous hyperplasia (AAH) as the
precursor of at least a subset of adenocarcinomas.1 AAH is
most frequently detected in lungs from patients bearing lung
cancers (9–20%), especially adenocarcinomas (up to 40%)
compared with squamous cell carcinomas (11%).2 Several
molecular changes frequently present in lung adenocarcino-
mas are also present in AAH lesions, and there is further
evidence that AAH may represent true preneoplastic lesions.1
The most important findings are the presence in AAHs of
K-ras (codon 12) mutations (40%),3 loss of LKB1 function
(20%),4 allelic losses in chromosomes 3p (20%), 9p (p16INK4a,
10%), 9q (50%), 17q, and 17p (TP53, 5%),5,6 and overex-
pression of cyclin D1 (70%), p53 (ranging from 10 to 60%),7
and survivin (50%).8 Despite the evidence that AAH is a
precursor lesion for a subset of lung adenocarcinomas, there
is general consensus that the pathogenesis of most adenocar-
cinomas is still unknown. The findings of relatively infre-
quent tyrosine kinase domain epidermal growth factor recep-
tor (EGFR) mutations in AAH lesions (three out of 40
examined)9,10 and no EGFR mutation11,12 or relatively low
frequency in true BACs of the lung9 support the concept that
genetic abnormalities of EGFR are not relevant in the patho-
genesis of alveolar types of lung neoplasia. In addition, Tang
et al.13 recently reported that EGFR mutation is an early event
in the pathogenesis of lung cancer, being identified in histo-
logically normal epithelium of small bronchi and bronchioles
adjacent to EGFR mutant lung adenocarcinomas in nine out
of 21 (43%) patients examined, but in none of the patients
without mutation in the tumor. These data further support the
notion than AAH lesions are not involved in the pathogenesis
of EGFR mutant lung adenocarcinomas.
BAC, ADENOCARCINOMA WITH
BRONCHIOLOALVEOLAR FEATURES, AND
ADENOCARCINOMA OF THE LUNG
The frequency of EGFR mutations has also been stud-
ied in patients with BAC, adenocarcinoma with BAC fea-
tures, and adenocarcinomas of the lung. Although responses
to EGFR tyrosine kinase inhibitors have been reported to be
higher14 and EGFR mutations were preferentially observed in
tumors having BAC features,12,15 we did not find association
with the BAC subtype of adenocarcinoma in 97 cases from
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the United States11 using the criteria stated by the 1999 WHO
classification of lung tumors.16,17
In addition to the WHO system, Noguchi et al.18,19 have
classified adenocarcinomas into different categories that have
different frequencies of genetic changes. Koga et al.20 re-
ported that p53 mutations were present in approximately 0%
of 17 pure BAC, 11% of 27 mixed adenocarcinoma with
BAC features, and 48% of 101 invasive adenocarcinomas.
Similar to the frequency of mutations, the frequency of p53
protein overexpression detected by immunohistochemistry
increased from 6% (2/32 tumors) in pure BAC to 28%
(27/133) in BAC with foci of active fibroblastic proliferation
(Noguchi type C) and to 40% (14/35) in adenocarcinoma.21
p53 mutation and protein overexpression were also correlated
with the size and invasive component of small peripheral
adenocarcinomas (5 mm: 41%; 5 mm: 20%).22,23
The frequency of allelic losses also increased signifi-
cantly during malignant progression. According to Noguchi’s
classification,18,19 frequencies of allelic losses at chromo-
somal loci 3p, 17p, 18q, and 22q were significantly lower in
BAC with or without alveolar collapse (Noguchi types A and
B, respectively) than in BAC with active fibroblastic prolif-
eration (Noguchi type C) in a series of 66 small peripheral
adenocarcinomas.24
The frequency and type of K-ras mutation in BAC are
related to the cytological features (mucinous versus nonmu-
cinous). This raises the question of whether the mucinous
form might represent a biological entity separate from the
nonmucinous form. Small series of tumors (all 50) from
patients with adenocarcinoma of the lung show that the K-ras
mutation is present in 73 to 100% of the mucinous types and
that the type of the mutation was usually G to A (codon 12),
whereas it was seen in 10 to 43% in the nonmucinous types,
usually in G to T transversions.25–27 Mutations at codon 12 of
the K-ras oncogene were found in 39% of 41 AAH, 42% of
18 adenocarcinomas, and none of five lung neoplasms that
were not adenocarcinomas. Of the patients with both an AAH
and a synchronous adenocarcinoma, more than half did not
have the mutation in both the AAH and the synchronous lung
adenocarcinoma, suggesting that peripheral adenocarcinomas
arise not always from AAH but sometimes directly from a
background of field cancerization.27
Adenocarcinomas with BAC features are also charac-
terized by an intense inflammatory reaction especially con-
taining alveolar neutrophils and macrophages. Increased
numbers of tumor-infiltrating neutrophils are linked to poorer
outcomes in these patients.28 Tumor environment drives local
neutrophil recruitment and activation via C-X-C chemokine
release such as interleukin-8 and epithelial cell–derived neu-
trophil activating protein 78 but also prolongs alveolar neu-
trophil survival through the production of soluble antiapop-
totic factors (granulocyte–macrophage colony–stimulating
factor and granulocyte colony–stimulating factor).29,30 The
mechanisms by which neutrophils influence the prognosis of
adenocarcinoma with BAC features could be multiple. It has
been postulated that the persistence of neutrophil alveolitis
would result in persistent release of proinflammatory media-
tors such as cytokines, proteases, and reactive oxygen and
nitrogen species that can damage DNA and activate onco-
genes.31,32 Among these factors released by neutrophils, he-
patocyte growth factor seems to be particularly involved in
the progression of these types of tumors, especially through
its mitogenic and scattering properties, favoring c-Met ex-
pressing tumor-cell migration along the alveolar basal mem-
brane.33 Lastly, neutrophils might be involved in luminal
tumor spread by promoting tumor-cell shedding (M. Wislez,
AACR 2004), described pathologically as the presence of
micropapillary clusters that are also involved in the mecha-
nism of aerogenous progression.34
GENOMIC AND PROTEOMIC STUDIES OF BAC
As mentioned before, BAC is thought to arise from
AAH and is potentially an intermediate to invasive adeno-
carcinoma. Extensive analyses of BAC using gene-expres-
sion profiling and proteomic-based studies have not yet been
performed and are only available for limited numbers of these
cancers. These types of studies may have the potential to
define similarity or differences in the observed types of adeno-
carcinoma of the lung. Of particular interest is the potential
regulatory pathway involved in the lepidic growth patterns of
BAC, which is different from most other adenocarcinomas of
the lung. The observation that some adenocarcinomas can ex-
hibit regions of BAC provides complexity and has resulted
in multiple pathological-based classifications.14,16–19 Genomic
studies have the potential to define the similarities as well as key
differences between BAC, adenocarcinomas with BAC features,
and adenocarcinomas of the lung.
Recent studies examining individual genes have hinted
at differences between BAC and adenocarcinomas. The tu-
mor suppressor in the lung cancer-1 gene encodes an adhe-
sion molecule and is frequently associated with LOH at that
locus in non–small-cell lung cancer. Both normal lung cells
and BAC retain expression of tumor suppressor in lung
cancer-1, whereas 63% of adenocarcinomas demonstrated
decreased expression detected by immunohistochemistry.35
BACs have very low p53 DNA mutation frequencies com-
pared with adenocarcinomas of the lung.20 LOH at the 3p
FHIT loci was observed in 43% of BAC, and 12th codon
K-ras mutations are detected in the mucinous form of BAC.36
A comparative LOH study between 14 BAC and 20 stage I
lung adenocarcinomas using nine chromosomal regions re-
vealed that the most frequently affected chromosomal regions
in BAC were 8q and 17p.37 In adenocarcinomas of the lung,
LOH at 1p, 3p, 7q, and 18q was more frequent than in BAC,
and fractional allele loss was greater in adenocarcinomas of
the lung than BAC.
Using immunocytochemistry to examine protein ex-
pression, detection of the thyroid transcription factor-1
(TTF-1), cytokeratin 7, and cytokeratin 20 were measured in
both mucinous and nonmucinous BAC.38 TTF-1 was detected
in 17% of mucinous and 94% of nonmucinous BAC, cyto-
keratin 7 was detected in 100% of mucinous and 23% of
nonmucinous BAC, and cytokeratin 20 was detected in 60%
of mucinous and 0% of nonmucinous BAC.38 In a study that
examined MUC protein expression in AAH, BAC, and ade-
nocarcinomas with BAC features, MUC1 decreased from
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AAH to BAC and from BAC to adenocarcinoma, whereas
MUC2, MUC5AC, MUC6, and depolarized MUC6 increased.39
Alterations in p53 and the increased expression of MUC1,
MUC5AC, and MUC6 were noted.
ADDITIONAL GENOMIC AND PROTEOMIC
STUDIES
A comparison of normal lung tissue and BAC using
oligonucleotide arrays was reported by Goodwin et al.40 and
identified 12 up-regulated and six down-regulated genes in
the BAC tumors. Although this analysis provides some in-
formation, a comparison of BAC and adenocarcinomas was
not included, which may be most relevant in defining critical
genes involved in the development of these cancers. We used
oligonucleotide arrays to examine gene expression in 14 BAC
and 73 adenocarcinomas.41 The most highly expressed genes
that were significantly different between the BAC tumors and
adenocarcinomas and higher in BAC included the surfactant
pulmonary-associated proteins A1, A2, C and D, MUC1,
TTF-1 and TTF-3, villin 2, and prostaglandin D2 synthetase.
Interestingly, higher mRNA expression for both fos and jun B
were detected in BAC, which may reflect an elevated AP-1
activity and upstream signaling events in these tumors. The
higher level of expression of surfactant genes is consistent
with the well-differentiated phenotypic characteristics of
BAC. TTF-1 was the most differentially expressed gene
between BAC and adenocarcinomas, consistent with the high
TTF-1 protein expression reported in BAC.38 Because of the
small numbers of tumors for our analyses, it was not possible
to divide the BAC tumors into separate categories such as
mucinous, nonmucinous, and mixed histology. Although we
found MUC1 mRNA present in both BAC and adenocarci-
nomas of the lung, the significantly increased expression in
BAC is consistent with the higher MUC1 protein levels that
have been reported in these tumors.39
Analysis of survival-related genes revealed prostaglan-
din D2 synthetase and neutrophil elastase 2 to be more highly
expressed in BAC than the other adenocarcinomas. In con-
trast, much lower levels of vascular endothelial growth factor
were detected in the BAC, possibly reflecting a lesser level of
angiogenesis and hypoxia in these tumors relative to the
adenocarcinomas. Adenocarcinomas also expressed increased
levels of metallothionein 2A and thioredoxin reductase
mRNA. We speculate that these genes may correspond to
smoking-related alterations because these genes may change
in response to reactive oxygen species originating from to-
bacco smoking or in response to inflammatory cells. Alter-
nately, the expression of thioredoxin reductase and metallo-
thionein 2 may reflect the higher rates of cell proliferation in
the lung adenocarcinomas relative to BAC.
Few, if any, large-scale proteomic analyses of BAC
have been reported. We examined the same BAC and lung
adenocarcinomas for mRNA using oligonucleotide arrays and
also at the protein level with two-dimensional gel electro-
phoresis and mass spectrometry.42 A total of 682 protein
spots were quantified, and 75 proteins were found to differ
significantly (p  0.05) between BAC and lung adenocarci-
nomas. Thirty-eight protein spots were successfully identified
using mass spectometry. Of interest were the relatively higher
expression of the ras-related protein RAB-14, glutathione-s-
transferase-pi, cytokeratin 7, and three isoforms of the sele-
nium-binding protein 1 in BAC compared with adenocarci-
nomas of the lung. Adenocarcinomas expressed higher levels
of phosphoglycerate kinase 1, pyruvate kinase M1/M2, and
stathmin (OP-18) compared with BACs. Increased phospho-
glycerate kinase 1 is consistent with higher hypoxia-induced
glycolysis in the adenocarcinomas of the lung relative to
BAC.42
Future studies that include sufficient numbers of the
various histological subtypes of BAC are needed to provide
insight into the similarities and differences among these
tumors and as compared with lung adenocarcinomas. The
NCI Director’s Challenge: Validation Study of Lung Adeno-
carcinomas will examine gene expression using Affymetrix
133A oligonucleotide arrays among approximately 500 tu-
mors. Thus, a relatively large number of BACs will be
included in this study, allowing potential gene pathways to
be defined that may be relevant to our understanding of the
growth- and cell-signaling systems in BAC. These analyses
will also incorporate detailed pathologic assessment of each
tumor so that the subtypes of each BAC can be compared. It
is expected that these data, made available to the research
community, will then stimulate further research into potential
new markers for early diagnosis and possible therapeutic
intervention strategies that may be effective for BAC.
FUTURE DIRECTIONS
The Committee responsible for Molecular Biology,
Genomics, and Proteomics in Bronchioloalveolar Carcinoma
outlined studies that will provide further insights into BAC.
The most important part of the meeting was partial agreement
and understanding about the interpretation of the pathological
classification. The participants in the meeting agreed on a
common set of descriptors for the pathological interpretation
of BAC that will be used more consistently in the future.
TABLE 1. Different Biological Properties in Atypical Adenomatous Hyperplasia, Pure Bronchioloalveolar Cancer,
Adenocarcinoma with Bronchioloalveolar Cancer Features, and Adenocarcinoma
Atypical Adenomatous
Hyperplasia
Bronchioloalveolar
Carcinoma
Adenocarcinoma with Bronchioloalveolar
Carcinoma Features
Adenocarcinoma
of the Lung
EGFR mutation 2 5% 10% 1 40%
TP53 mutations Not reported 2 0% 2 10% 1 50%
p53 by immunohistochemistry Not reported 2 5% 1 30% 1 50%
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Upcoming technological improvements will provide
additional insights into the biology of BAC. These will
include the increasing ability to detect genetic changes in
BAC and adenocarcinomas including, but not be limited to,
EGFR, HER-2/neu, B-raf, K-ras, and TP53. In addition, there
is the ability to detect genetic loss in the whole genome using
studies with single-polynucleotide polymorphisms or array
chromosomal genomic hybridization. There is increasing
ability to use small and smaller amounts of DNA and DNA
from paraffin-embedded tissues. Future studies will provide
information on the degree of genetic changes seen in early
lesions (1cm) that are being detected more often as com-
puterized tomographic scanning of the chest is becoming
more widely used. These findings can be compared with the
more advanced lesions. The genetic changes can also provide
insights into the clonality of the BACs to determine whether
the multiple lesions in the lungs arise from single or multiple
clones. Table 1
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